当前位置：易推广 > 上海陶术生物科技有限公司 > 产品展示
企业档案
会员类型：会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
易推广会员：5年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
企业类型：生产商 【已认证】
注册资金：人民币万 【已认证】
产品数：86101
参观次数：3504258
自主品牌
已选条件
-
T10898Samuraciclib hydrochlorideICEC0942 hydrochloride；CT7001 hydrochloride
Samuraciclib hydrochloride is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold higher than CDK1, CDK2 (IC50 is 578 nM), CDK5 and CDK9 respe
价 格：￥电议型 号：T10898产 地：中国大陆
-
T63650Samuraciclib hydrochloride hydrate；化合物 Samuraciclib hydrochloride hydrateSamuraciclib hydrochloride
Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive, orally active inhibitor of CDK7 (IC50: 41 nM). Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines (GI50: 0.2-0.3 μM) and exhibits potent antitumor effects.
价 格：￥电议型 号：T63650产 地：中国大陆
-
T61835Samuraciclib；化合物 SamuraciclibSamuraciclib
Samuraciclib (CT7001) is a potent, selective, and orally active inhibitor of CDK7, with an ATP-competitive nature. It effectively inhibits CDK7 with an IC 50 value of 41 nM. Furthermore, Samuraciclib demonstrates remarkable selectivity ratios, with 45-fold, 15-fold, 230-fold, and 30-fold selectivity over CDK1, CDK2 (IC 50 of 578 nM), CDK5, and CDK9, respectively. Notably, Samuraciclib has been found to inhibit the growth of breast cancer cell lines, exhibiting GI 50 values ranging between 0.2-0.
价 格：￥电议型 号：T61835产 地：中国大陆
-
T35650Samuraciclib trihydrochloride；Samuraciclib trihydrochlorideSamuraciclib trihydrochloride
Samuraciclib (CT7001) trihydrochloride is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib trihydrochloride displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib trihydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib trihydrochloride has anti-tumor effects[1][2].
价 格：￥电议型 号：T35650产 地：中国大陆
-
T10898Samuraciclib hydrochloride；化合物Samuraciclib hydrochlorideICEC0942 hydrochloride|||CT7001 hydrochlorid
Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold higher than CDK1, CDK2 (IC50 is 578 nM), CDK5 and CDK9 respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride has anti-tumor effects.
价 格：￥电议型 号：T10898产 地：中国大陆
